Engaged in diverse basic, translational and clinical research, our faculty routinely publish in prestigious journals and successfully compete for major grants from national funders.
Ducharme-Crevier L, Furlong-Dillard J, Jung P, Chiusolo F, Malone MP, Ambati S, Parsons SJ, Krawiec C, Al-Subu A, Polikoff LA, Napolitano N, Tarquinio KM, Shenoi A, Talukdar A, Mallory PP, Giuliano JS Jr, Breuer RK, Kierys K, Kelly SP, Motomura M, Sanders RC Jr, Freeman A, Nagai Y, Glater-Welt LB, Wilson J, Loi M, Adu-Darko M, Shults J, Nadkarni V, Emeriaud G, Nishisaki A. (2024) Safety of primary nasotracheal intubation in the pediatric intensive care unit (PICU). Intensive Care Med Paediatr Neonatal (May)
Rhythm Evaluation for AntiCoagulaTion for Atrial Fibrillation (REACT AF). Anne Curtis (Co-Investigator). NIH. $66,278. 8/1/2023-7/1/2029.
Posttranslational modifications of glucocorticoid receptor associated with drug resistance in prostate cancer. Remi Adelaiye-Ogala (Principal Investigator). NCI/NIH. 4/1/2024-5/1/2029.
Residency Training in Mental and Behavioral Health (PCTE-RTMB). Andrew Symons (Co-Principal Investigator). Health Resources and Services Administration. $2,500,000. 1/1/2023-12/1/2028.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Michael Duffey (Co-Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-9/1/2028.
Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Mark Parker (Principal Investigator). NIH National Eye Institute. 1/1/2018-9/1/2028.
Preventing and Reversing Interstitial Fibrosis in HFpEF. Brian Weil (Co-Investigator). Veteran's Affairs Merit Review Award. $709,984. 10/1/2020-9/1/2028.
Human miRNA Sequencing. Norma Nowak (Principal Investigator). VA. $183,213. 9/1/2023-9/1/2028.
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers. Wilma Hofmann (Co-Investigator). NIH/NCI. 8/1/2023-7/1/2028.
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers. Michael Buck (Co-Investigator). NCI. $3,823,553. 8/1/2023-7/1/2028.
VA Merit Review, 2IO1BX002659, Preventing and Reversing Interstitial Fibrosis in HFpEF. John Canty, Jr. (Principal Investigator). Department of Veterans Affairs. $709,984. 7/1/2020-6/1/2028.
Site Specific Drug Delivery with Light-responsive Conjugates for Photobiomodulation. Elizabeth Wohlfert (Co-Investigator). NIH. $2,011,250. 8/1/2023-6/1/2028.